Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

6.3K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.3K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.8K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.8K
Lipid Catabolism01:25

Lipid Catabolism

1.3K
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
1.3K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

972
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
972
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Obesity01:24

Obesity

1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Genetic Testing in Endocrinology Practice: A Single-Center Experience Focused on Lipid and Monogenic Diabetes Disorders.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same author

Genetic testing in kidney transplantation and living kidney donor risk assessment.

Kidney international·2026
Same author

Spectrum of DNA Variants in Southwestern Ontario Patients with Familial Hypercholesterolemia.

CJC open·2026
Same author

Heterozygous pathogenic PPARG variants in patients with severe hypertriglyceridemia.

Journal of clinical lipidology·2025
Same author

Genetic Testing in Adults over 50 Years with Chronic Kidney Disease: Diagnostic Yield and Clinical Implications in a Specialized Kidney Genetics Clinic.

Genes·2025
Same author

Implementation of a Kidney Genetic Service Into the Diagnostic Pathway for Patients With Chronic Kidney Disease in Canada.

Kidney international reports·2025

Related Experiment Video

Updated: Mar 10, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K

Familial partial lipodystrophy presenting as metabolic syndrome.

Darwin Chan1, Adam D McIntyre2, Robert A Hegele2

  • 1School of Medicine, McMaster University, Hamilton, Ontario, Canada.

Journal of Clinical Lipidology
|December 7, 2016
PubMed
Summary

This study details a novel LMNA gene mutation causing familial partial lipodystrophy type 2 (FPLD2), presenting with metabolic syndrome. It emphasizes the condition

Keywords:
Dunnigan-type 2 familial partial lipodystrophyFPLD2Lamin A/CMetabolic syndrome

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.9K
Fiber Type and Subcellular-Specific Analysis of Lipid Droplet Content in Skeletal Muscle
11:50

Fiber Type and Subcellular-Specific Analysis of Lipid Droplet Content in Skeletal Muscle

Published on: June 8, 2022

5.2K

Related Experiment Videos

Last Updated: Mar 10, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.9K
Fiber Type and Subcellular-Specific Analysis of Lipid Droplet Content in Skeletal Muscle
11:50

Fiber Type and Subcellular-Specific Analysis of Lipid Droplet Content in Skeletal Muscle

Published on: June 8, 2022

5.2K

Area of Science:

  • Genetics and Molecular Biology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Familial partial lipodystrophy type 2 (FPLD2) is a rare genetic disorder characterized by lipodystrophy and metabolic complications.
  • The LMNA gene encodes lamins, crucial structural proteins in the nuclear envelope, and mutations are linked to various lipodystrophic syndromes.

Observation:

  • A patient presented with clinical features consistent with FPLD2, exhibiting a heterozygous p.R545H missense mutation in the LMNA gene.
  • The patient's initial presentation mimicked metabolic syndrome, underscoring the diagnostic challenge and overlap between these conditions.

Findings:

  • The identified LMNA mutation (c.1634 G > A) is associated with a spectrum of metabolic derangements, including type 2 diabetes mellitus, fatty liver disease, polycystic ovarian syndrome, and hypertriglyceridemia.
  • This mutation was previously noted in a heart failure database, suggesting a potential link between FPLD2 and cardiovascular complications.

Implications:

  • Early identification of FPLD2 is crucial for managing associated metabolic and potentially cardiac conditions.
  • Understanding the genotype-phenotype correlation of LMNA mutations can improve diagnostic accuracy and patient care strategies.
  • Further research into the pathogenic mechanisms linking LMNA mutations to metabolic syndrome and heart failure is warranted.